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Sumnlllry - Thirty quinoxalinesbearing a substituted anilino group on position 2. a carl>oethoxy or 
carboxy group on position 3 and a trifJuoromethyl group on position 6 or 7 of theheterocycle were pre-
pared in order to evaluate in vitro anticancer activity. Preliminary screening perfonned at NeI showed that 
most derivatives exhibited a moderate to strong growth inhibition activity on various turnor panel cell lines 
between 10-5 and 10-4 molar concentrations. Interesting selectivities were also recorded between 10-8 and 
1(t6.M for a few compounds. One single compound exhibited good activity against Candida albicans. 
INTRODUCTION 
lsosteric replacement of the heterocyclic nuclei 
of methotrexate and trimetrexate with quinoxa-
line represents our current research program 
devoted to envisage new potential antifolate deriv-
atives l -4. In this context we have so far described 
the compounds of formula 1, 2, 3 (Fig. 1) many of 
which exhibited very promising in vitro total 
growth inhibition activity and a few have been 
selected for in depth in vivo screeningS·6• In par-
ticular~ we have discovered and recently reported 
that when the phenyl group in position 3 of qui-
noxaline ring has been replaced by a carboethoxy 
group and in po~ition 2 we placed an aminoben-
z~lglutamate moiety (formula 3 R=C02Et; Rl=H; 
R =Et) the percent tumor growth inhibition was 
markedly high and accompanied with an interest-
in5 anti-HIV and very. promising antifungal activ-ity . On the other hand. the ester was more active 
than the corresponding acid which in turn was 
superior in antifungal (Candida albicans) test. 
On the basis of these findings we have now pre-
pared the esters 4a-o and the acids 5a-o of Fig. 2 
in order to verify the influenc,e of both carbethoxy 
and carboxy group in the series of 2-anilino deriv-
atives previously described3 . 
CHEMISTRY 
The previously described chIoroquinoxalines 6-87 
were reacted with the appropriate anilines (9) in 
refluxing ethanol to give the desired esters 4a-o in 
fair yields (Table I) according to Scheme I. The acids 
5a-o were obtained after alkaline hydrolysis of 4a-o. 
R=H;NH2;CF3;NOz 
R'cH;NHCOCH3;NHI 
Z R -Ph; 2-Th;COzEt;CH3 
Fig. 1 





































































































Mp's are uncorrected and were recorded on a Kofler or a 
Electrothermal melting point apparatus. UV spectra are qual-
itative and were recorded in nm for solution in ethanol with a 
Perkin-Elmer Lambda 5 spectrophotometer. IR spectra are for 
Nujol muIlsand were recorded on Perkin-Elmer 781 instru· 
ments. 'H NMR spectra were recorded at 200 MHz with a 
Varian XL-200 instrument using TMS as internal standard. 
Elemental analyses were performed at Laboratorio di Microan-
alisi. Dipartimento di Scienze Farmaceutiche. UniversitA di 
Padova. The analytical results for C,H,N were within .:t 0,4% of 
thll theoretical values. 
lNTERMEDlATES 
The intermediate chloroquinoxaIinesnecessary for this work • 
as well as the quinoxalinones required for their preparation. 
were obtained as previously described7• 
General procedure for preparation of 3-ethoxycar-
bonyl-2-(R1,R2,R3)substituted anilinoquinoxalines 
(4a-o) 
A mixture of the suitable 2-chloroquinoxaline (6-8) (3 mmol) 
and the appropriate commercially available aniline suspended 
in ethanol (IO ml)was stirred under reflux for I3 h. On cool-
ing the fonned precipitates were IDtered off and washed with 
ethanol. The yellow to red-orange products were further puri~ 
6ed by recrystallization from ethanol-water. Yields. m.p.s. ana-
lytical and spectroscopic data are reported in Table I. 
"" General procedure for preparation of 2-(RI,R2,R3) 
substituted anilinoquinoxaline-3-carboxylic acids 
(5a-o). 
A suspension of ester (4a-o) (l mmol) in a mixture of etha-
nol (10 ml) and IM NaOH aqueous solution (5 m!) was stirred 
under reflux for 1 h. On cooling. the precipitate. constituted by 
the sodium salts of Sa-a. was collected and washed with etha-
nol. The solids. slightly soluble in water, were dissolved in a 
mixture of water ethanol and the resulting solution. made aci-
dic with 2M HCI aqueous solution. gave semi-solid precipitates 
or dusts of the acids (5a-o) that were collected and thoroughly 
washed with water. Yields. m.p.s. analytical andspectroscopic 
data are reported in Table I. 
B) PHARMACOLOGY 
Evaluation of anticancer and anti mv activity was per-
formed on 30 compounds referring to structures 4,5a-o of 
--------~)P~ 4a-o 
t· 
R_~):W; ~ ~N.& ,.. " D ,R2 
5a-o 
Fig. 2 and Table I at the National Cancer Institute of Bethesda, 
following the known8 in vitro disease-oriented antitumor 
screening program against a panel of 60 human tumor cell 
lines and anti-HIV drug testing system9• The anticancer activity 
of each compound is deduced from dose-response curves and 
is presented in three different Tables according to the data 
provided by NCI. Antifungal activity was investigated at the 
Institute of Microbiology and Virology of Sassari University. 
In Table n the response paramete~ GIso.TGI and LCso 
refer to the concentration of the agent in the assay that pro-
duced 50% growth inhibition, total growth inhibition. 50% 
cytotoxicity respectively and are expressed as Mean Graph 
Midpoints. 
In Table III we reported the activities of those compounds 
which showed percent growth inhibition greater than 4004> on 
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TABLE r - Yields, analytical and spectroscopic data of the comPounds 4a-o and 5a-o 
Compel M.p. Yield Analysis vrnax Amax IH-Nmr. I) (J in H1)(*); solvent: A= CDC13; B= DMSO-d6~ 
"C % for c:m- I nrn(EtOH) C=CDCI3+DMSO~(I:ll D=CDCl3+DMSQd6(3:1) 
1!'lujQll 
4a 127-128 85 Ct8H17N3OJ 3310,3290, 417,276,208 A 10.15 (JH, s, NH), 8.02 (lH, d, J 8.2, amm) 7.80 {2H, ad. J 9.0. 
(a) 1700 H-YS}, 7.78-7-65 (2H, rn, amrn), 7.49-7.44 (lH, ID. arorn), 
6.96 (2H, ad, J 9,0. B-2',6'), 4.60 (2H. q. CH2l. 3.84 (3H. s, 
OMe). 1.53 (3B, I, Me) 
4b 148-150 94 C19H19N30 4 3310,3290, 296,223,205 A 10.21 (!H. s. NH). 8.03 (lB. d.l 8.4, acorn), 7.78-7.66 OH,m. 
1700 amm). 7.50-7.36 (2H. rn. amm), 6.91 (lH, d, J 8.6. H-5'), 4.60 
(2H, q, CH2), 3.97 (3H, s, OMe), 3.91 (3H, s, OMe), 1.54 (3H, 
toMe) 
4«: 172-174 -'92 C2oH2I N30 5 3310,1690 295,225,208 A 10.31 (tH. s. NH).8.04 (lB. d, J 8.6, arom)7.78·7.76 (2B' m, 
Mom).7.56-1.44 (lB. m, arom). 7.28 (2R, &<;. H·2',6'), 4.61 
(2H. q. CB2). 3.94 (6H, S, 3',s'-OMc). 3.S7 (3R, s, 4'-OMe), 
1.55 (3R. t, Me) 
4d 143';145 92 CI7H 1302N3D2 3310,3270, 41S,292,222. A 10.45 OH, s.NH), 8.29 (lB, d, J 2.4, R-2'). 8.05 (IH, d, J 8.8. 
3190,1700 206 H-8), 7.88-1.74 (2H, m, amrn). 7.67 (lH, dd, J 8.2 and 2.2, H· 
6'),7.58-7.48 (lH, m. H-6), 7.41 (lH, d J 8.8, H-5'}.4.60 (2H, q. 
CH2l, 1.54 (3H, t, Me) 
4e 155-'56 83 CI7Hr4FN3D2 3310,3290. 424,285,222, A 10.29 (IH. s, NH), 8.04 (!H, d, J 8.4, H-8), 7.90·7.70 (4H, m. 
3280.1695 202 amm), 7.52-7.45 (IH, m. amm), 7.13-7.05 (2H, m, amm). 4.60 
(2H, q, CH2), 1.53 (3H, t, Me) 
4f 137-138 93 C19H16F3N3OJ 3310,3290, 441,287,220. A 10.21 (tH. s. NH); 8.11 (IH. d. J 8.2. H·5), 8.04 (1H, s. H-8), 
1705 203 7.77 (2H. cl. J 9.0. H-3·S). 7.60 (2H, dd. J 8.2 md 1.8, H-6), 
6.97 (2H, d, J 9.0,H-2',6'), 4.61 (2H, q, CH2). 3.85 (3H, s. 
OMe), 1.53 (3H. t, Me) 
4g 178-179 87 C20H ISF3N30 4 3310.3290. 316.290.208 A 10.26 (IH, s, NH). S.12 (tH. d. 111.6·H-S), 7.99 (1H. s, H-8), 
1700 7.61 (lH. dd. J 8.6 and 1.8, H·6), 7.51 (IH, d, J 2.4, H·2').7.40 
(lH. dd. J 8.6 and 2.4, H-6'). 6.92 ClH. d. J 8.6. H-5'). 4.61 (2H, 
q. CH2). 3.92 (3H. s, OMe), ISS (3H, 1, Me) 
41 189-191 89 C21 R2oF3N30 5 3290.1710 310,291,206 A 10.37 (JH, s, NH), 8.15 (m. d, J 8.8. H·5). 7.97 (lH. s. H·8). 
7.65 (IH. dd, J 8.8 and 1.4, H·6).7.21 (2H, s. H-2'.6'), 4.62 (2H. 
q. CH2), 3 . .95 (6H, s 3',S'-OMe). 3.88 (3H, s. 4··OMe),. I.S6 
(3H. t, Me) 
41 167-168 90 ~t 8Ht2C12F3N3D2 3260;1700 416.304,287. B 10.21 (JR. s. NH), 8.29 (IH. d, J 2.8, H·2'). 8.19 (lH. d. J 8.2. 
217 H-5), 8.10 (m. a s, H·8). 7.90 (lH. dd. J 8.6 and 2.S. "-6'). 7.82 
(lH. dd, 18.2 and 2.2. H-6). 7.60 (IH. d, J 8.8. "·5'),4.50 (2H, 
q, CH2). 1.43 (3", t, Me) 
4j 155-156 81 CI8H I3F4N:30z 3300.1700 429,283,218, A 10.35(1H, s, NH), 8.14 (lH, d. 8.8, H.5), 8.05 (m. s. H-8). 
202 7.88-7.80 (2H, m, H-2',6'). 7.64 (IH. dd, J 8~8 and 1.8, H-6), 
7.17 -7.05 (2H, rn. H-3'S), 4.62 (2H. q, CH2), 1.55 (3H. t, Me) 
4k 137-138 90 CI9HI6F3N3OJ 3310.3290, 415.275.208 A 10.29 (!H, s, NH), 8.32 (1H. s, H-5), 7.81-7.52 (2H, In, H-7.8), 
1690 7.77 C2H, d. J 9.2, H-3·S). 6.96 (2H, d. J 9.2. H-2'.6'),4.60 
(2H, q, CHll, 3.85 (3H.s.OMe). 1.53 (3H, t. Me) 
41 205~207 92 C2oHISFJN30 4 3270,1705 410,320,293, A 10.34 (In, s, NH), 8.34 (IH, S, H-5), 7.90-7.75 (2H, m. H·7,8), 
206 7.59 (IH, cl. J 8.8 and 2.4, H-6,), 6.92 (IH, d. J 8.8, H-5'), 4.61 
. (2H. q, CH2), 3.96 (lB. s. OMe), 3.92 (3H. s, OMe), 1.54 (3H, 
t, Mc) 
4m 181-183 83 C21H2oF3N30S . 32S0.1700 428.316,293 • A 10.44 (lH. S, NH), 8.36 (lH. s, H·S), 7.95-7.75 (2H. In, H-7,8), 
224.207 7.24 (2H. s. H-2'.6'). 4.62 (2H, q, CH2). 3.94 (6H, s, 3'.S-OMe), 
3.88 (3R. s. 4'-OMe). 1.55 (3H, t, Me) 
40 162·164 78 CI8H 12C12F3N3D2 3260,1700 410.300sh,289. A 10.58 (tH. s. NH). 8.38 (IH, s. H-5), 8.25 (1H, d. J 2.4, H·2,), 
219, 7.95~7.82 (2H, m. H-5',6'), 7.67 m, dd, J 8.6 and 2.4. H-7). 
206 7.44 (lH. d. J 8.6, H-8), 4.61 (2H. q. CH2), 1.54 (3H, 1. Mc) 
40 125-127 81 CI8H13F4N3D2 3280,1690 419,28S)18, A 10.43 (IH, S, NIl), B.36 (lH, s, H·5), 7.92- 7.Bl (4}1. m. amm). 
202 7.16-7.07 (2H, DJ, H-3',5'). 4.61 (2H. q. CH2). 1.55 (3H. t. Me) 
5a ISO-lSI 94 CI6H13N303 3520,3320, 393.300sh,269, C 10.41 (IH. s. NH). 7.97-7.93 (IH, DJ, acom). 7.81 (2H. d. J 9.0. 
3280,1700 200 H·3',S'), 7.72~7.70 (IH. RI, arom), 7.53 (IH. ID, amm), 6.93 (2H, 
d, J 9.0, H-2',6'), 4.44 (I H, br s, CooH). 3.81 (3H, S, 4'·OMe) 
5b IS2-153 95 C17H ISN30 4 3280,1730 4OS.300sh.287. D 10.41 (IH. s, NH), 8.00 (lH, d. 1 8.2, H-8), 7.80-7.70 (3H. m. 
1.07 acorn). 7.55-7.45 (lH, In, amm), 7.36 {lH. dd, J 8.8 and 2.2, H-
6').6.90 (m. d, J 8.B. H-5'). 4.88 (lH. br 50 COOH), 3.96 (3H. 
s. OMc). 3.90 (3H. s, OMc) 
(to be collliltued) 
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TABLE I - (conlinuetl) 
Compel M.p. Yield Analy5is Vmax Amax IH-Nmr, ~ (J in Hz)("); solvent: A- CDCl3: B= DMS()..d6; 
"C % for cnrl nm(EtOH) C=CDCl3+DMSO-d6(1:t) D::CDC13+DMSOd6(3:1) 
(Nujol) 
Se 173-174 87 C18H17N30 5 3$00:3360, 389,300sh,273, D 10.57(lH, 5, NH), 7.99 (lH, d, J 8.8, arom), 7.73~7.68 (2H, m. 
3280,1670 203 arom), 7.56-7.45 (lH, m, arom), 7.31 (2a 5; H-2"6'), 4.52 (lH, 
br s. COOH), 3.91 (6H. s. 3',5'-OMe). 3.78 (3H. So 4'..QMe) 
Sd 163-165 95 C15Hg02N3D2 3320,3280, 392.294,216 D 10.78 (lH. So NH), 834 (lH, So H-2'), 8.03 (IH. d, J 8.4. arom), 
0.25 H2O 1710 730-7~75 (2H, m. atom), 7.70 (lH. m, arom). 7.60-7.50 (lH, m, 
acorn), 7.43 (JR, d, J 8.4, H-S'), 5.02 (IH, br s, COOH) 
Se 147-149 88 CI5HIOFN3OJ 3340,1710 398,281,217 D 10.58(1R, s, NR), 8.01 (IR, d, J 8.4, H-8), 7.95-7.85 (2H, ni, 
arom), 7.78-7.70 (2H, m, arom), 7.55-7.45 (IH, m. arom), 7.15-
7.04 (2H, m, H-3',5'). 4.65 (IH. a s. COOH) 
Sf 140-141 72 C17HI2N30 3 3500,3310. 415,304,284, D 10.52 (IH, 5, NH). 8.13 (lH, d, J 8.6,8-5),8.02 (tB,s, H-8), 
3280,1690 204 7.8 (28, d, I 8.8, H-3'S). 7.64(lH, dd. J8.6 and 1.4, H-6), 6.96 
(2H, d, J 8.8. H-2',6'), 4.08 (lH, a s, COOH), 3.85 (3H, 5, 4'-
OMe) 
Sg 171-173 81 CJ8H I4FJN30 4 3540.3400, 417.311,284, D 10.54 (lH, 5, NH), 8.12 (lH, d, J 8.4, H-5). 7.96 (lH, 5,H-8), 
1700 206 7.64 (!H. d, J 8.4, H-6). 7.58 ClH, d, J 2.0, H-2'). 7.42 (IH, cid. 
J 8.6 and 2.0, H-6'.), 6.94 (lH, d, J 8.6, H-5'), 4.00 (I H, br 5, 
COOH). 3~1 (3H, 5, OMe), 3.84 (3H, S, OMe) 
Sh 148-150 72 C19HI6F3N305 3530,3360, 414.384,307, B 10.54 (IH, s, NH). 8.15 (lH, d, J 8.4, R-5), 8.02 (IH, s. H-8), 
H2O 3280,1700 200 7.74 (1H. d. J 8.4. H-6), 1.30 (28, s, H-2',6'), 3.86 (6H, 5, 3',5'-
OMe), 3.69 (3H, s, 4'-OMe), 3.53 (lA, a s, COOH) 
Si 183-185 83 C16H8C12F3N3D2 3260,1680 399,298,214 0 1O.81(1H,5, NH),8J7 (lH, d, J 8.6, H-5), 8.08 (IH. s, H-8), 
7.78-7.68 (3H, m, H-6,2',6'), 7.47 (tH, d. J 8.8, H-5'), 4.52 (IH, 
brs,COOH) 
Sj 166-168 95 CJ6H9F4N307 3630,3280, 404,295,279, C 10.63 (1H, S, NH), 8.13 (lH, d, J 8.0, H-5), 8.03 (IH, lit H-8), 
0.25 H20 3180,1700 214 8.00-7.88 (2H, m, H-2',6'), 7.68 (lH. d, J 8.0, H-6),7.25-7.10 
(2H, m. H-3'S), S.IO (!H, brs, COOH) 
Sk' 103-105 95 ct7Hl2F3N3OJ 3500,3380, 407,305,282, P 10.57{IH, s, NH), 8.31 (IH, s. H-5), 7.82-7.75 (2H, m. H-7,8), 
3260,1700 232,204 7.80 (2H, d, J 9.0, H-3',5'), 6.95 (2H, d, J 9.0, H-2',6'), 5.12 
(IH, br s, COOH), 3.84 (3R, 5, 4'-OMe) 
51 ... 86 CI8H 14F3N304 3300,1710 395,301,269. C 10.59 (IH, S, NH},8.22 (IH, s, H-5), 7.95-7.68 (2H, m. H-7,8), 
217 7.67 (lH, S, H-2'), 6.35. (IH, d, 7.8, H-6'), 6.93 (lA. d, J 7.8, H-
5'), 4.66 (1H, br s, COOH), 3.8& (3H, S, OMe), 3.82 (3H,. S, 
OMe) 
Srn .... C19HI6F3N30 5 3300,1750 303,205 0 10.74 (18,5, NH), 8.34 (IH, s, H-5), 7.95-7.80 (2H, m, H-7,8). 
7.28 (2H, s. H-2',6'), 4.55 (IH, br s, CooH), 3.93 (6H, 5, 3',5'· 
OMe), 3.84 (3H. 11. 4'-OMe) 
Sn 176-178 90 C16H8C12FJN302 3360,3290, 393,297,288, D 10.97 (IH, S, NH), 8.35 (IH, s, H-5), 832 (IH, d, J 2.4, H-2'). 
1750 214 8.00-7.86 (2H, m, H-7,8), 7.73 (lH, dd, J 8.8 and 2.4. H-6'), 
7.47 (lH, do J 8.8. H-5'). 3.84 (lH. br s, CooH) 
So 179-181 86 CJ@I9F4N3D2 3280,1750 398,280,227. D 10.73 (IH. s. NH),8.32 (lH. S, H-5), 7.95-7.80 (4H, m. H-
213 5,6,2',6'),7.18-7.02 (2a m. H-3',5'), 5.28 (lH, br s, COOH) 
(1t) J of triplet and quartet corresponding to Me-CH2 are not reported because well corresponding to the data of the literature; 
(**) Melts at 120 ·C, and decomposes at 148 ·C; (***) Melts at 170 ·C, solidifies and remelted at 250°C. 
subpaneI cell-lines at Molar concentration of 10-4 whereas in 
Table IV is reported the activity of those compounds which 
exhibited both Significant selectivity and growth inhibition at 
10".5 M. The most diluted concentrations (10-8, 10"7, 10-6 .M) 
were considered in the case of compounds 4, 5 which showed 
high selectivity (Table V). 
In Table VI we reported the preliminary results of both anti-
fungal activity against Candida albicans and anti-RIV protec-
tion. 
RESULTS AND DISCUSSION 
From the data of Table IT we can deduce that 
the average sensitivity of all cell lines towards the 
tested agent, represented as Mean. Graph Mid-
points, falls in the range 10-5 -:- 10-4 Molar con-
centrations, Mean Graph Midpoints for com-
pounds 4a-o show that whereas GIso was nearly 
2-Anilino-3-carboxy-quinoxaIines with anticancer activity 535 
TABLE IT - -loglOGIso, -log 1 oTGI, -IOglOLCsO Mean 
Graph Midpoints (MG-MID) of in vitro Inhibitory 
Activity Test for Compounds 4a-o and 5a-o 
against Human Tumor Cell Lin~ 
Compd 
-
108100150 -loglOTGI -logIOLCSO 
4a 4.32 4.06 4.00 
4b 4.06 4.00 4.00 
4c 4.01 4.00 4.00 
4d 432 4.04 4.00 
4e 4.44 4.11 4.01 
4r 4.23 4.03 4.00 
42 4.10 4.01 4.00 
4h 4.00 4.00 4.00 
4i 4.09 4.00 4.00 
4j 4.J3 4.01 4.00 
4k 4.07 4.00 4.00 
41 4.02 4.00 4.00 
4m 4.00 4.00 4.00 
40 4.08 4.00 4.00 
40 4.28 4.03 4.00 
Sa 4.21 4.01 4.00 
Sb 4.]9 4.00 4.00 . 
Se 4.23 4.01 4.00 
Sd 4.64 4.10 4.00 
Se 4.51 4.04 4.00 
Sf 4.73 4.28 4.05 
Sa 4.53 4.07 4.00 
Sb 437 4.02 4.00 
Si 5.14 4.62 4.23 
5j 4.75 4.25 4.03 
5k 4.54 4.06 4.00 
51 4.55 4.09' 4.01 
Sm 4.61 4.21 4.03 
5n 4.87 4.46 4.16 
50 4.79 4.20 4.01 
(MG-MID): Mean Graph Midpoints. the average sensitivity of 
all cell lines towards the test agent: (4) from NCI 
equal to both TGI and LCso (4b,c,g,h,i,l,m,n) only 
a few subpanel cell-lines were sensitive .. On the 
contrary in the series of compounds 5a-o we 
recorded an high degree of inhibition activity 
between 10-5 -:- lQ-4 Molar concentrations as expres-
sed as Mean Graph Midpoints. The data of Table 
ID were in line with the above observation. From 
the data of Table IT and ill we can establish a 
decreasing order of turnor growth inhibition activity 
for each compound (5i>Sn>Sf>Sm>50>4e>Sd>Sl) 
as expressed by both TGI and LCso. The most 
active compounds (5i,5n) were also the most cyto-
toxic as expressed as LC50• 
. According to Table IV compound Si mantained 
high inhibition activity at 1O-s Molar concentration 
in 39 over 60 subpanel cell-lines with particular 
significativity on leukemia. colon. breast and pros-
tate cancer. A few other compounds were in 
decreasing order endowed with cell-line sensitivity 
at this concentration: compound Sn (16 cell- lines 
over 60). So (12 over 60). 4e (11 over 60), .5j (10 
over 60), in the remaining compounds (4d,g,h,o 
and 5a,d,f,k) we could only observe some cell-line 
sensitivity. The data of Table V show that some 
compounds (4a,b,c;h) and (5a,b,d,e,g,h,i,k,l) man-
tained a certain degree of tumor growth inhibition 
at the most diluted concentrations on some sub-
panel cell-lines as result of their cell-line selectivity. 
Interestingly COinpound 4c exhibited a promis-
ing antifungal activity against Candida albicans 
(MIC=1.9 Jig/ml). Compound4d exhibited a mod-
erate HIV protection (Table VI). 
Structure-activity relationships show that between 
the series of the esters 4a-o and the corresponding 
acids 5a-o the last were in general superior in turnor 
growth jnhibition activity. A positive influence of a 
trifluoromethyl group does not distinguish between 
the substitution positions in the quinoxalinering. 
Comparison of the activity of 3',4'-dichloro-3',4'-
dimethoxy- and 3',4',S'~trimethoxyanilino quinoxa-
lines (4g,h,i,l,m,n) and (5g,h,i,I,m,n) with the cor-
responding analogues 1 previously described3 
bearing hydrogen,phenyl,methyl assusbstituent on 
,position 3 evidentiated that the tumor growth inhi-
bitionwas of the same order of magnitude only for 
compounds (Sg,h,l,m) whereas in the case of com-
pounds 4 these were in general less active than 
their above cited analogues. On the contrary in the 
case of Si this compound was more active than the 
corresponding methyl and phenyl analogues. 
In conclusion we can say that the electronegativ-
ity of the carboxyl group to some extent can posi-
tively influence the anticancer activity of these 
anilinoquinoxalines. 
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